| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
L-XMP Sodium does not have a pharmacological target. It is a biochemical reagent and a metabolic intermediate in the purine biosynthesis pathway. XMP is the precursor to guanosine monophosphate (GMP) in the de novo purine synthesis pathway.
|
|---|---|
| ln Vitro |
The utilization of microbiological technologies to produce xanthoside 5'-monophosphate sodium salt (XMP) at a high yield facilitates its application as a flavoring ingredient in food and as a chemical intermediate in the purine antimetabolite production process. In addition to being useful in the synthesis of synthetic polynucleotides, sodium salt of xanthoside 5'-monophosphate is also useful for studying the structure of nucleic acids, protein synthesis, and genetic coding [1].
In vitro, L-XMP Sodium is used as a substrate or reference standard in biochemical assays. It serves as an intermediate in purine metabolism and can be utilized to study enzymes involved in purine biosynthesis, such as GMP synthetase. Detailed in vitro activity data is not applicable as it is a metabolic intermediate rather than a biologically active molecule. |
| ln Vivo |
In vivo, L-XMP Sodium functions as a metabolic intermediate in purine metabolism. It is involved in the biosynthesis of guanine nucleotides. The compound is not administered as a therapeutic agent but is used as a research tool to study purine metabolism.
|
| Enzyme Assay |
Non-cellular assays for L-XMP Sodium involve analytical chemistry methods to quantify XMP levels. These include HPLC, LC-MS, or enzymatic assays. The compound's identity and purity are confirmed by standard analytical methods such as NMR and mass spectrometry.
|
| Cell Assay |
In vitro cellular experiments involve supplementing cell culture media with L-XMP Sodium to study purine metabolism. Cells are cultured in media containing the compound, and nucleotide levels are measured by HPLC or LC-MS.
|
| Animal Protocol |
In vivo animal studies for L-XMP Sodium are not typically performed as it is a metabolic intermediate rather than a therapeutic agent.
|
| ADME/Pharmacokinetics |
L-XMP Sodium has a molecular weight of 408.17 g/mol and a molecular formula of C₁₀H₁₁N₄Na₂O₉P. It is a solid powder. The compound is soluble in water.
|
| Toxicity/Toxicokinetics |
L-XMP Sodium has low toxicity. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
L-XMP Sodium (xanthosine 5'-monophosphate disodium salt, 5'-xanthylic acid disodium salt) is an intermediate in purine metabolism. It is used in research studies of genetic code, nucleic acid structure, and DNA, RNA, and protein synthesis. This product is for research purposes only and is not for human therapeutic use.
|
| Molecular Formula |
C10H11N4NA2O9P
|
|---|---|
| Molecular Weight |
408.17
|
| Exact Mass |
408.006
|
| CAS # |
25899-70-1
|
| PubChem CID |
10287649
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
573
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])[O-])O)O)NC(=O)NC2=O.[Na+].[Na+]
|
| InChi Key |
QQPVYRBCIRHGSZ-LGVAUZIVSA-L
|
| InChi Code |
InChI=1S/C10H13N4O9P.2Na/c15-5-3(1-22-24(19,20)21)23-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17;;/h2-3,5-6,9,15-16H,1H2,(H2,19,20,21)(H2,12,13,17,18);;/q;2*+1/p-2/t3-,5-,6-,9-;;/m1../s1
|
| Chemical Name |
disodium;[(2R,3S,4R,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
|
| Synonyms |
LXMP Sodium; L XMP Sodium; L-XMP Sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~612.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (122.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4500 mL | 12.2498 mL | 24.4996 mL | |
| 5 mM | 0.4900 mL | 2.4500 mL | 4.8999 mL | |
| 10 mM | 0.2450 mL | 1.2250 mL | 2.4500 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
